Predict your next investment

Private Equity
smedvigcapital.com

See what CB Insights has to offer

Investments

60

Portfolio Exits

24

About Smedvig Capital

Smedvig Capital was founded in 1996 and has invested over £500m of internal capital. The firm invests £2-10m in fast-growing UK and Nordic businesses. Smedvig Capital looks for ambitious teams that are building businesses that have the potential to become market leaders.

Smedvig Capital Headquarter Location

Ryger House 11 Arlington Street

London, England, SW1A 1RD,

United Kingdom

+44 207 451 2100

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Smedvig Capital News

Antidote Technologies Raises $23M in Funding

Jun 3, 2021

Antidote Technologies , a US and UK based digital health company, raised $23M in funding. The round was led by LBO France, which is investing $10m through its Digital Health 2 fund, with participation from existing investors Merck Global Health Innovation Fund, Smedvig Capital, and Octopus Ventures, who are investing $13.2m in total. In conjunction with the funding, Sebastien Woynar and Franck Noiret of LBO France will join the Antidote Board as a director and an observer, respectively. The company intends to use the funds to enhance its clinical trial search engine, launch new products and services (including data insights), and expand its presence internationally. Led by Laurent Schockmel, CEO, Antidote is a digital health company which uses precision recruitment to match the right patients with the right trials. This is achieved through the integration of data-driven technologies, digital expertise, deep domain experience, an extensive diverse partner network, and personalized patient and site services. Antidote was launched as TrialReach and is based in New York, NY, Carmel, IN, and London, U.K. FinSMEs 03/06/2021

Smedvig Capital Investments

60 Investments

Smedvig Capital has made 60 investments. Their latest investment was in Antidote as part of their Series D on June 6, 2021.

CBI Logo

Smedvig Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/3/2021

Series D

Antidote

$23.2M

No

LBO France, Merck Global Health Innovation Fund, and Octopus Ventures

5

1/18/2021

Series A

proSapient

$10M

Yes

24Haymarket, and Guy Hands

2

1/29/2020

Series A

Yumpingo

$10M

Yes

David Cantu, and Keith Taylor

11

9/5/2019

Series A

Subscribe to see more

$99M

Subscribe to see more

10

4/30/2019

Series E

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/3/2021

1/18/2021

1/29/2020

9/5/2019

4/30/2019

Round

Series D

Series A

Series A

Series A

Series E

Company

Antidote

proSapient

Yumpingo

Subscribe to see more

Subscribe to see more

Amount

$23.2M

$10M

$10M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

LBO France, Merck Global Health Innovation Fund, and Octopus Ventures

24Haymarket, and Guy Hands

David Cantu, and Keith Taylor

Sources

5

2

11

10

10

Smedvig Capital Portfolio Exits

24 Portfolio Exits

Smedvig Capital has 24 portfolio exits. Their latest portfolio exit was Spirable on August 17, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

8/17/2021

Acquired

Genius Sports Group

3

7/14/2021

Acq - Fin

SFW Capital Partners

2

10/15/2019

Acquired

TV Time

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

8/17/2021

7/14/2021

10/15/2019

00/00/0000

00/00/0000

Exit

Acquired

Acq - Fin

Acquired

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

Acquirer

Genius Sports Group

SFW Capital Partners

TV Time

Subscribe to see more

Subscribe to see more

Sources

3

2

1

10

10

Smedvig Capital Acquisitions

3 Acquisitions

Smedvig Capital acquired 3 companies. Their latest acquisition was Picture Production Company on September 01, 2010.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

9/1/2010

Acq - Fin

Acq - Fin

1

5/14/2008

Acq - Fin - III

Subscribe to see more

$991

$99M

Subscribe to see more

10

4/15/2004

Leveraged Buyout

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/1/2010

5/14/2008

4/15/2004

Investment Stage

Acq - Fin

Acq - Fin - III

Leveraged Buyout

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Total Funding

$99M

$99M

Note

Acq - Fin

Subscribe to see more

Subscribe to see more

Sources

1

10

10

Smedvig Capital Team

8 Team Members

Smedvig Capital has 8 team members, including current Chief Executive Officer, Johnny Hewett.

Name

Work History

Title

Status

Johnny Hewett

Chief Executive Officer

Current

Cristian Young

Chief Financial Officer

Current

Alistair Cairns

Managing Director

Current

Robert Toms

Managing Director

Current

Einar Gamman

SR Bank, ABB, and Procom Venture

Chief Executive Officer

Former

Name

Johnny Hewett

Cristian Young

Alistair Cairns

Robert Toms

Einar Gamman

Work History

SR Bank, ABB, and Procom Venture

Title

Chief Executive Officer

Chief Financial Officer

Managing Director

Managing Director

Chief Executive Officer

Status

Current

Current

Current

Current

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.